José Lopes, PhD, managing science editor —

Saniona‘s investigative treatment for Prader-Willi syndrome, Tesomet tablets, were well-tolerated in preclinical toxicology studies, the company announced. The positive results support the safe dosing of Tesomet in long-term Phase 2 and Phase 3 clinical trials, the company said. Results also revealed that Tesomet, a fixed-dose combination of tesofensine…

Results of an Alizé Pharma clinical trial showed that the company’s investigative therapy AZP-531 is safe and blocks patients’ tendency to eat excessively in Prader-Willi syndrome (PWS). The study, “AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled…